AGRX RSI Chart
Last 7 days
-5%
Last 30 days
35.7%
Last 90 days
-74.1%
Trailing 12 Months
-93.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 12.9M | 16.3M | 20.0M | 19.6M |
2022 | 5.7M | 6.7M | 8.4M | 10.9M |
2021 | 1.6M | 2.5M | 3.3M | 4.1M |
2020 | 0 | 0 | 0 | 749.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 03, 2023 | coiante scott m | acquired | - | - | 20,000 | chief financial officer |
Jun 28, 2023 | gilmore geoffrey | acquired | - | - | 20,216 | chief administrative officer |
Jun 28, 2023 | welsh amy | acquired | - | - | 13,500 | chief commercial officer |
Jun 28, 2023 | altomari alfred | acquired | - | - | 46,463 | chief executive officer |
Jun 28, 2023 | conway robert g | acquired | - | - | 13,500 | chief supply chain officer |
Jun 28, 2023 | korner paul | acquired | - | - | 13,500 | chief medical officer |
Jun 08, 2023 | fischer seth h. z. | acquired | - | - | 935 | - |
Jun 08, 2023 | torrente josephine | acquired | - | - | 935 | - |
Jun 08, 2023 | hubbard john w | acquired | - | - | 935 | - |
Jun 08, 2023 | carson sandra | acquired | - | - | 935 | - |
Which funds bought or sold AGRX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Apr 05, 2024 | CWM, LLC | sold off | -100 | - | - | -% |
Mar 11, 2024 | VANGUARD GROUP INC | new | - | 39,930 | 39,930 | -% |
Feb 14, 2024 | STATE STREET CORP | unchanged | - | -4,988 | 21,144 | -% |
Feb 14, 2024 | GROUP ONE TRADING, L.P. | unchanged | - | -4.00 | 20.00 | -% |
Feb 14, 2024 | COMERICA BANK | unchanged | - | -2.00 | 8.00 | -% |
Feb 14, 2024 | INVESTOR AB | new | - | 3,420 | 3,420 | -% |
Feb 14, 2024 | Royal Bank of Canada | added | 214 | 1,000 | 2,000 | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | added | 50.07 | 6,624 | 37,532 | -% |
Feb 13, 2024 | Tower Research Capital LLC (TRC) | added | 49.52 | 1,130 | 6,388 | -% |
Unveiling Agile Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Agile Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 359.2B | 85.6B | 9.34 | 4.19 | ||||
MRK | 323.0B | 61.4B | 140.05 | 5.26 | ||||
AMGN | 166.9B | 29.5B | 44.36 | 5.65 | ||||
PFE | 157.1B | 46.5B | -113.14 | 3.37 | ||||
GILD | 80.7B | 27.1B | 14.25 | 2.98 | ||||
TEVA | 15.6B | 15.8B | -27.18 | 0.99 | ||||
MID-CAP | ||||||||
PRGO | 4.4B | 4.7B | -349.99 | 0.95 | ||||
ALKS | 4.1B | 1.7B | 9.38 | 2.36 | ||||
BHC | 2.9B | 9.0B | -6.3 | 0.32 | ||||
AMPH | 2.0B | 644.4M | 14.84 | 3.17 | ||||
SMALL-CAP | ||||||||
TLRY | 1.6B | 743.2M | -4.6 | 2.18 | ||||
TXMD | 22.0M | 1.3M | -2.14 | 16.92 | ||||
ACRX | 17.1M | - | -0.93 | 0.22 | ||||
AGRX | 2.5M | 19.6M | -0.17 | 0.13 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Agile Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | -45.7% | 3,614,500 | 6,662,000 | 5,503,000 | 3,813,000 | 3,995,500 | 3,002,000 | 2,126,000 | 1,761,000 | 1,513,500 | 1,287,000 | 1,185,000 | 116,000 | 749,000 |
Cost Of Revenue | -11.5% | 2,191,000 | 2,477,000 | 2,307,000 | 2,003,000 | 1,653,000 | 1,425,000 | 2,231,000 | 1,527,000 | 5,701,000 | 2,711,000 | 1,145,000 | 1,161,000 | - |
Gross Profit | -66.0% | 1,423,500 | 4,185,000 | 3,196,000 | 1,810,000 | 2,342,500 | 1,577,000 | -105,000 | 234,000 | -4,187,500 | -1,424,000 | 40,000 | -1,045,000 | 467,000 |
Operating Expenses | -33.1% | 5,474,500 | 8,185,000 | 8,322,000 | 8,518,000 | 9,220,000 | 20,285,000 | 11,293,000 | 15,807,000 | 18,170,500 | 14,350,000 | 16,691,000 | 15,177,000 | 17,208,000 |
S&GA Expenses | -22.3% | 3,729,000 | 4,800,000 | 4,570,000 | 4,670,000 | 6,845,500 | 5,560,000 | 7,411,000 | 10,553,000 | 13,004,500 | 9,386,000 | 11,977,000 | 9,253,000 | 10,669,500 |
R&D Expenses | -92.3% | 54,000 | 705,000 | 703,000 | 763,000 | 352,000 | 788,000 | 856,000 | 1,257,000 | 1,673,000 | 1,593,000 | 862,000 | 2,123,000 | 3,012,000 |
EBITDA Margin | -7.5% | -0.66 | -0.61 | -1.02 | -1.31 | -2.36 | -4.79 | -7.59 | -10.97 | -15.87 | -19.09 | -25.49 | -35.27 | - |
Interest Expenses | -10.7% | 304,500 | 341,000 | 372,000 | 402,000 | 432,000 | 1,004,000 | 823,000 | 872,000 | 1,000,000 | 999,000 | 993,000 | 922,000 | 904,000 |
Income Taxes | - | - | - | - | - | - | - | - | -4,675,000 | - | - | - | - | - |
Earnings Before Taxes | -459.3% | -4,468,500 | -799,000 | -3,809,000 | -5,390,000 | -3,930,000 | -5,930,000 | -5,168,000 | -15,060,000 | -19,530,000 | -16,772,000 | -17,637,000 | -17,128,000 | -17,620,000 |
EBT Margin | -5.9% | -0.74 | -0.70 | -1.17 | -1.58 | -2.76 | -5.44 | -8.45 | -12.01 | -17.33 | -20.72 | -27.45 | -37.91 | - |
Net Income | -459.3% | -4,469,000 | -799,000 | -3,809,000 | -5,389,000 | -3,930,000 | -5,930,000 | -5,168,000 | -10,385,000 | -19,530,000 | -16,772,000 | -17,637,000 | -17,128,000 | -17,620,000 |
Net Income Margin | -5.9% | -0.74 | -0.70 | -1.17 | -1.58 | -2.33 | -4.88 | -7.75 | -11.19 | -17.33 | -20.72 | -27.45 | -37.91 | - |
Free Cashflow | -52.9% | 172,000 | 365,000 | -8,519,000 | -1,595,000 | -1,559,000 | -16,703,000 | -2,941,000 | -14,877,000 | -16,673,000 | -18,645,000 | -15,414,000 | -14,739,000 | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -5.8% | 10.00 | 11.00 | 13.00 | 14.00 | 14.00 | 18.00 | 33.00 | 29.00 | 39.00 | 37.00 | 52.00 | 59.00 | 73.00 | 89.00 | 103 | 109 | 50.00 | 34.00 | 25.00 | 26.00 | 22.00 |
Current Assets | -5.3% | 10.00 | 10.00 | 12.00 | 11.00 | 11.00 | 15.00 | 18.00 | 14.00 | 24.00 | 22.00 | 37.00 | 44.00 | 57.00 | 73.00 | 89.00 | 95.00 | 35.00 | 20.00 | 11.00 | 12.00 | 8.00 |
Cash Equivalents | -11.0% | 3.00 | 3.00 | 3.00 | 4.00 | 5.00 | 6.00 | 13.00 | 4.00 | 19.00 | 15.00 | 26.00 | 16.00 | 14.00 | 24.00 | 39.00 | 94.00 | 34.00 | 18.00 | 11.00 | 12.00 | 8.00 |
Inventory | 13.6% | 3.00 | 2.00 | 3.00 | 2.00 | 1.00 | 2.00 | 2.00 | 3.00 | 1.00 | 3.00 | 3.00 | 2.00 | - | - | - | - | - | - | - | - | - |
Net PPE | -25.7% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00 | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 |
Liabilities | 14.0% | 27.00 | 23.00 | 25.00 | 23.00 | 20.00 | 21.00 | 30.00 | 35.00 | 35.00 | 26.00 | 28.00 | 24.00 | 24.00 | 23.00 | 22.00 | 18.00 | 4.00 | 3.00 | 3.00 | 3.00 | 2.00 |
Current Liabilities | 18.5% | 21.00 | 18.00 | 15.00 | 19.00 | 13.00 | 12.00 | 29.00 | 26.00 | 29.00 | 10.00 | 12.00 | 9.00 | 7.00 | 7.00 | 6.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.00 |
Long Term Debt | - | 2.00 | - | - | - | 1.00 | - | - | - | - | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 16.00 | 15.00 | - | - | - | - | - |
LT Debt, Current | -4.7% | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 13.00 | 12.00 | 17.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -Infinity% | -16.32 | - | - | - | -5.54 | 6.00 | 2.00 | 3.00 | 4.00 | 11.00 | 25.00 | 35.00 | 49.00 | 66.00 | 81.00 | 91.00 | 46.00 | 0.00 | 273 | 271 | 20.00 |
Retained Earnings | -1.1% | -423 | -418 | -417 | -414 | -408 | -404 | -398 | -393 | -383 | -363 | -346 | -329 | -312 | -295 | -279 | -268 | -260 | -254 | -249 | -246 | -241 |
Additional Paid-In Capital | 0.1% | 407 | 406 | 406 | 405 | 403 | 402 | 401 | 388 | 387 | 374 | 372 | 364 | 362 | 361 | 360 | 359 | 306 | 286 | 273 | 271 | 262 |
Accumulated Depreciation | - | 0.00 | - | - | - | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 30.1% | 3.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 5.00 | - | - | - | 14.00 | - | - | - | 101 | - | - | - | 197 | - | - | - | 52.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -52.9% | 172 | 365 | -8,519 | -1,595 | -1,559 | -16,703 | -2,934 | -14,751 | -16,618 | -18,580 | -15,336 | -14,668 | -17,342 | -15,320 | -6,765 | -7,884 | -3,270 | -5,080 | -2,378 | -4,961 | -3,136 |
Share Based Compensation | 28.2% | 563 | 439 | 481 | 498 | 524 | 536 | 669 | 764 | 866 | 887 | 843 | 742 | 711 | 647 | 839 | 621 | 415 | 378 | 479 | 490 | 803 |
Cashflow From Investing | - | - | - | - | - | - | - | -7.00 | -126 | -55.00 | 4,935 | 18,395 | 16,185 | 7,527 | -173 | -47,880 | -164 | -68.00 | - | - | - | - |
Cashflow From Financing | -75.2% | -487 | -278 | 6,875 | 778 | 660 | 9,821 | 12,225 | -523 | 21,081 | 2,262 | 6,595 | 484 | 115 | 210 | 166 | 67,494 | 19,447 | 12,894 | 1,404 | 8,670 | -5,939 |
Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Statements of Operations and Comprehensive Loss | |||
Revenues, net | $ 19,593 | $ 10,884 | $ 4,101 |
Cost of product revenues | 8,978 | 6,836 | 10,718 |
Gross profit | 10,615 | 4,048 | (6,617) |
Operating expenses: | |||
Research and development | 2,225 | 3,253 | 6,246 |
Selling and marketing | 17,769 | 30,369 | 43,444 |
General and administrative | 10,505 | 11,860 | 14,698 |
Loss on disposition of assets | 11,122 | ||
Total operating expenses | 30,499 | 56,604 | 64,388 |
Loss from operations | (19,884) | (52,556) | (71,005) |
Other income (expense) | |||
Interest income | 78 | 80 | 25 |
Interest expense | (1,419) | (3,131) | (3,914) |
Unrealized gain on warrant liability | 6,760 | 25,520 | 3,827 |
Total other income (expense), net | 5,419 | 22,469 | (62) |
Loss before benefit from income taxes | (14,465) | (30,087) | (71,067) |
Benefit from income taxes | 4,675 | ||
Net loss | $ (14,465) | $ (25,412) | $ (71,067) |
Net loss per share (basic) (in dollars per share) | $ (6.71) | $ (58.79) | $ (1,464.20) |
Net loss per share (diluted) (in dollars per share) | $ (6.71) | $ (58.79) | $ (1,464.20) |
Weighted-average common shares (basic) (in shares) | 2,156,726 | 432,219 | 48,536 |
Weighted-average common shares (diluted) (in shares) | 2,156,726 | 432,219 | 48,536 |
Comprehensive loss: | |||
Net loss | $ (14,465) | $ (25,412) | $ (71,067) |
Other comprehensive income: | |||
Unrealized (loss) on marketable securities | (3) | ||
Comprehensive loss | $ (14,465) | $ (25,412) | $ (71,070) |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 2,557 | $ 5,246 |
Accounts receivable, net | 3,392 | 3,377 |
Inventory, net | 2,738 | 1,332 |
Prepaid expenses and other current assets | 843 | 1,403 |
Total current assets | 9,530 | 11,358 |
Property and equipment, net | 75 | 177 |
Right of use asset | 412 | 695 |
Other non-current assets | 238 | 2,012 |
Total assets | 10,255 | 14,242 |
Current liabilities: | ||
Long-term debt, current portion | 1,515 | 1,426 |
Notes payable, current portion | 191 | |
Accounts payable | 9,574 | 7,734 |
Accrued expenses | 9,131 | 3,908 |
Lease liability, current portion | 366 | 319 |
Total current liabilities | 20,777 | 13,387 |
Lease liabilities, long-term | 100 | 466 |
Warrant liability | 5,696 | 5,934 |
Total liabilities | 26,573 | 19,787 |
Commitments and contingencies (Note 12) | ||
Stockholders' deficit | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 4,850 issued and no shares outstanding at December 31, 2023 and no shares issued and outstanding at December 31, 2022 | ||
Common stock, $0.0001 par value, 300,000,000 shares authorized, 2,963,657 and 859,402 issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 4 | |
Additional paid-in capital | 406,846 | 403,157 |
Accumulated deficit | (423,168) | (408,702) |
Total stockholders' deficit | (16,318) | (5,545) |
Total liabilities and stockholders' deficit | $ 10,255 | $ 14,242 |
 | Mr. Alfred F. Altomari |
---|---|
 | agiletherapeutics.com |
 | Pharmaceuticals |
 | 22 |